<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="States. Here, we update the recent understanding in clinical characteristics," exact="diagnosis" post="strategies, as well as clinical management of COVID-19 in"/>
 <result pre="the global efforts to outline references for prevention, basic research," exact="treatment" post="as well as final control of the disease. Being"/>
 <result pre="unrelated to the size of the country. Subject terms Viral" exact="infection" post="Respiratory tract diseases Facts The Covid-19 pandemic exploded first"/>
 <result pre="deaths worldwide as of 25 May 2020, the spread of" exact="infection" post="still seems difficult to contain. Both the availability of"/>
 <result pre="the territory may be responsible for the vast heterogeneity in" exact="infection" post="containment and mortality. Open questions The therapy, especially in"/>
 <result pre="virus. The initial step of SARS-Cov-2 viral entry during the" exact="infection" post="is the binding of the viral trimeric spike protein"/>
 <result pre="al.6. In this review, we update the latest clinical characteristics," exact="diagnosis" post="strategies, as well as clinical management of the COVID-19"/>
 <result pre="COPD^: 42 (4%) COPD 234 (18.1%) Chronic hepatitis B virus" exact="infection" post="N/A 5 (4.4%) N/A Chronic liver disease: 28 (3%)"/>
 <result pre="40 (3.1%) Median days from symptom onset to date of" exact="diagnosis" post="(median, interquartile range) N/A 10 (7â€&quot;13) 5.1 (95% confidential"/>
 <result pre="study performed on the Diamond Princess cruise ship, repeated PCR" exact="testing" post="of 3711 quarantined passengers and crew members showed that"/>
 <result pre="patients (161 symptomatic and 30 asymptomatic). They found that the" exact="infection" post="rates of transmission rate in symptomatic cases was 6.3%"/>
 <result pre="4.1% in asymptomatic patients, indicating the importance of identification and" exact="isolation" post="of asymptomatic patients in the effort of containment the"/>
 <result pre="the spread of the virus21. Importantly, for large-scale screening, antibody" exact="testing" post="should be combined with PCR to avoid asymptomatic viral"/>
 <result pre="viral spreading. Diagnosis of COVID-19 Nucleic acid tests The definitive" exact="diagnosis" post="of the disease relies on the identification of viral"/>
 <result pre="right time using the adequate protocol is a key in" exact="diagnosis" post="of the infection. Besides in the respiratory tract, viral"/>
 <result pre="COVID-19 patients are first of choice to collect for the" exact="detection" post="of viral nuclear acid. Collecting and testing upper respiratory"/>
 <result pre="collect for the detection of viral nuclear acid. Collecting and" exact="testing" post="upper respiratory specimens would be ideal considering the feasibility"/>
 <result pre="that it is an adequate non-invasive test for monitoring and" exact="diagnosis" post="of the infections25. To increase the sensitivity of the"/>
 <result pre="test results. A false-positive test could result in an unnecessary" exact="quarantine" post="and therapy while a false-negative diagnosis may allow infected"/>
 <result pre="result in an unnecessary quarantine and therapy while a false-negative" exact="diagnosis" post="may allow infected patients to spread the virus. Therefore,"/>
 <result pre="many healthcare personnel have caused wanton community transmission before correct" exact="testing" post="allowed isolation and tracking. Therefore, tests that are able"/>
 <result pre="personnel have caused wanton community transmission before correct testing allowed" exact="isolation" post="and tracking. Therefore, tests that are able to be"/>
 <result pre="of COVID-19 including symptoms and epidemiology) COVID-19 cases, the positive" exact="detection" post="rate is extremely high (98.6%) when PCR is performed"/>
 <result pre="the serological tests could be used together with nuclei acid" exact="detection" post="to increase the sensitivity of tests. In China, some"/>
 <result pre="versatility of serological assays make them invaluable tools for COVID-19" exact="diagnosis" post="and efforts to produce antibody detection kits on a"/>
 <result pre="invaluable tools for COVID-19 diagnosis and efforts to produce antibody" exact="detection" post="kits on a huge scale have begun to be"/>
 <result pre="above, CT should not be used alone to make the" exact="diagnosis" post="of COVID-19. Fig. 5 Computer tomography image of COVID-19."/>
 <result pre="interstitial pneumonia. Clinical management At present, there are no specific" exact="treatment" post="with confirmed efficacy for COVID-19 and the therapeutic protocol"/>
 <result pre="80 SLE patients who took long-term oral HCQ showed SARS-CoV-2" exact="infection" post="or appeared to have related symptoms. The study found"/>
 <result pre="body temperature recovery time were strongly reduced in the HCQ" exact="treatment" post="group. Over 80% (25 of 31) of the patients"/>
 <result pre="Over 80% (25 of 31) of the patients in HCQ" exact="treatment" post="group showed improvement in pneumonia compared with the matched"/>
 <result pre="immune response at the early stage is critical for controlling" exact="infection" post="and the antiviral effect of HCQ is still in"/>
 <result pre="antiviral activity or clinical benefit of this combination for the" exact="treatment" post="of our hospitalized patients with severe COVID-19 (ref. 43)."/>
 <result pre="to say, at late stage of ARDS, controlling secondary bacterial" exact="infection" post="should not take lightly. In addition to treatment, CQ/HCQ"/>
 <result pre="found to have better efficacy compared with controls for MERS-CoV" exact="infection" post="in animal experiments and case reports46â€&quot;49. LPV/r was therefore"/>
 <result pre="be obtained in vivo37. In SARS-CoV-2-infected rhesus macaques, therapeutic remdesivir" exact="treatment" post="was found to reduce viral load when given early56."/>
 <result pre="for viral infection. Camostat mesylate seems rather specific, since SARS-Cov-2" exact="infection" post="requires TMPRSS2 for the priming of the viral S"/>
 <result pre="clinical studies reported that low or physiologic dose of corticosteroids" exact="treatment" post="could have clinical benefits to earlier reversal of shock,"/>
 <result pre="28-day survival rate82. IL-6 inhibitor, which was used as a" exact="treatment" post="for rheumatoid arthritis and CRS associated with CAR-T cell"/>
 <result pre="population is essential for anti-IL-6 treatment84. Upstream of that, the" exact="treatment" post="with inhibitors of TNF-Î² could be applied, but there"/>
 <result pre="of transmissibility of SARS-CoV-2 in feces, it indeed challenged the" exact="quarantine" post="given the high infectivity of the virus. Notably, PCR"/>
 <result pre="positive again in a small proportion of patients, although no" exact="infection" post="cases of these close contactors had been reported. Therefore,"/>
 <result pre="recommend that patients recovered and discharged should be continue to" exact="quarantine" post="for another 14 days. Preventive measures to minimize recurrence"/>
 <result pre="and mouth protection, testing, use of digital data and targeted" exact="quarantine" post="should be reinforced, see Fig. 6 and also ref."/>
 <result pre="full implementation of all proposed measure of containment (hygiene recommendations," exact="physical distancing," post="nose and mouth protection, testing, digital data tracking, selected"/>
 <result pre="by combining six main actions: social distance, masks, hygiene recommendations," exact="contact tracing," post="extensive use of early diagnosis tools, and confirmed and"/>
 <result pre="distance, masks, hygiene recommendations, contact tracing, extensive use of early" exact="diagnosis" post="tools, and confirmed and suspected cases quarantine. We learnt"/>
 <result pre="transmission of COVID-19. JAMA10.1001/jama.2020.2565 (2020) 21.ChenYet al.The epidemiological characteristics of" exact="infection" post="in close contacts of COVID-19 in Ningbo cityChin. J."/>
 <result pre="close contacts of COVID-19 in Ningbo cityChin. J. Epidemiol.2020410 22.LoeffelholzMJTangYWLaboratory" exact="diagnosis" post="of emerging human coronavirus infectionsâ€&quot;the state of the artEmerg."/>
 <result pre="in posterior oropharyngeal saliva samples and serum antibody responses during" exact="infection" post="by SARS-CoV-2: an observational cohort studyLancet Infect. Dis.20202056557432213337 26.Winichakoon,"/>
 <result pre="patientsChin. Med. J. (Engl.).20201331039104332118639 28.Al-AbdelyHMet al.Middle east respiratory syndrome coronavirus" exact="infection" post="dynamics and antibody responses among clinically diverse patients, Saudi"/>
 <result pre="36.Ai, T. et al. Correlation of chest CT and RT-PCR" exact="testing" post="in coronavirus disease 2019 (COVID-19) in China: a report"/>
 <result pre="and projection of optimized dosing design of hydroxychloroquine for the" exact="treatment" post="of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin."/>
 <result pre="39.Chen, J. et al. A pilot study of hydroxychloroquine in" exact="treatment" post="of patients with common coronavirus disease-19 (COVID-19). J. Zhejiang"/>
 <result pre="serological analysis of a recent Middle East respiratory syndrome coronavirus" exact="infection" post="case on a triple combination antiviral regimenInt. J. Antimicrob."/>
 <result pre="SARS coronavirus and MERS coronavirusâ€&quot;a possible reference for coronavirus disease-19" exact="treatment" post="option. J. Med. Virol. 556â€&quot;563. 10.1002/jmv.25729 (2020). 50.ChenJet al.Efficacies"/>
 <result pre="10.1002/jmv.25729 (2020). 50.ChenJet al.Efficacies of lopinavir/ritonavir and abidol in the" exact="treatment" post="of novel coronavirus pneumoniaChinese J. Infect. Dis.2020388689 51.CaoBet al.A"/>
 <result pre="in rhesus monkeysNature201653138138526934220 54.de WitEet al.Prophylactic and therapeutic remdesivir (GS-5734)" exact="treatment" post="in the rhesus macaque model of MERS-CoV infectionProc. Natl"/>
 <result pre="65.SooYOYet al.Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone" exact="treatment" post="in SARS patientsClin. Microbiol. Infect.20041067667815214887 66.HungIFNet al.Convalescent plasma treatment"/>
 <result pre="methylprednisolone treatment in SARS patientsClin. Microbiol. Infect.20041067667815214887 66.HungIFNet al.Convalescent plasma" exact="treatment" post="reduced mortality in patients with severe pandemic influenza A"/>
 <result pre="al.The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the" exact="treatment" post="of severe acute respiratory infections of viral etiology: a"/>
 <result pre="J. Respir. Crit. Care Med.201819775776729161116 76.LeeNet al.Effects of early corticosteroid" exact="treatment" post="on plasma SARS-associated coronavirus RNA concentrations in adult patientsJ."/>
 <result pre="trialâˆ—Crit. Care Med.20164427528126584195 83.National Health Commission of China. Diagnosis and" exact="treatment" post="of pneumonia caused by 2019 new coronavirus (trial version"/>
 <result pre="(trial version 7). http://www.gov.cn/zhengce/zhengceku/2020-03/04/5486705/files/ae61004f930d47598711a0d4cbf874a9.p [cited 2020 Mar 19]. 84.XuXet al.Effective" exact="treatment" post="of severe COVID-19 patients with TocilizumabProc. Natl Acad. Sci."/>
 <result pre="with TocilizumabProc. Natl Acad. Sci. USA2020117109701097532350134 85.RichardsonPet al.Baricitinib as potential" exact="treatment" post="for 2019-nCoV acute respiratory diseaseLancet2020395e30e3132032529 86.AhmedAet al.Ruxolitinib in adult"/>
</results>
